Polyclonal Rabbit anti‑Rat ACTRIIB / ACVR2B Antibody (FITC, aa342‑482, WB) LS‑C693533
Polyclonal Rabbit anti‑Rat ACTRIIB / ACVR2B Antibody (FITC, aa342‑482, WB) LS‑C693533
Antibody:
ACTRIIB / ACVR2B Rabbit anti-Rat Polyclonal (aa342-482) (FITC) Antibody
Overview
Antibody:
ACTRIIB / ACVR2B Rabbit anti-Rat Polyclonal (aa342-482) (FITC) Antibody
Specifications
Description
ACVR2B antibody LS-C693533 is an FITC-conjugated rabbit polyclonal antibody to rat ACVR2B (ACTRIIB) (aa342-482). Validated for WB.
Target
Rat ACTRIIB / ACVR2B
Synonyms
ACVR2B | Activin A receptor type IIB | Activin receptor type-2B | ActR-IIB | ACTRIIB | Activin receptor type IIB | Activin A receptor, type IIB | HTX4
Reactivity
Rat
(tested or 100% immunogen sequence identity)
Conjugations
FITC.
Also available
Unconjugated or conjugated with
Biotin,
Cy3,
HRP,
APC,
PE,
APC, Cy7.
Purification
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
Immunogen
Recombinant ACVR2B (Gly342-Ile482) expressed in E. coli.
Specificity
The antibody is a rabbit polyclonal antibody raised against ACVR2B.
Applications
- Western blot
- Applications tested for the base form of this product only
Presentation
PBS, pH 7.4, 0.02% Sodium Azide, 50% Glycerol
Storage
Avoid repeated freeze/thaw cycles. Store at 4°C for frequent use. Aliquot and store at -20°C for 12 months.
Restrictions
For research use only. Intended for use by laboratory professionals.
Guarantee
This antibody carries the LSBio 100% Guarantee.
LSBio Guarantee
Featured Products
Species:
Human
Applications:
Western blot, ELISA
Species:
Human, Mouse
Applications:
IHC, Western blot
Species:
Human, Mouse
Applications:
IHC, IHC - Paraffin, Western blot
Species:
Human
Applications:
Western blot, ELISA
Species:
Human
Applications:
IHC, Western blot, ELISA
Species:
Human
Applications:
Western blot, ELISA
Request SDS/MSDS
To request an SDS/MSDS form for this product, please contact our Technical Support department at:
Technical.Support@LSBio.com
Requested From: United States
Date Requested: 11/3/2024